Viatris Inc. (VTRS)

NASDAQ: VTRS · IEX Real-Time Price · USD
11.94
+0.11 (0.93%)
At close: Mar 28, 2024, 4:00 PM
12.00
+0.06 (0.50%)
After-hours: Mar 28, 2024, 7:02 PM EDT
0.93%
Market Cap 14.02B
Revenue (ttm) 15.43B
Net Income (ttm) 54.70M
Shares Out 1.19B
EPS (ttm) 0.05
PE Ratio 238.80
Forward PE 4.20
Dividend $0.48 (4.02%)
Ex-Dividend Date Mar 8, 2024
Volume 11,455,574
Open 11.81
Previous Close 11.83
Day's Range 11.78 - 12.02
52-Week Range 8.74 - 13.62
Beta 1.14
Analysts Sell
Price Target 11.00 (-7.87%)
Earnings Date May 6, 2024

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more]

Sector Healthcare
CEO Scott Andrew Smith
Employees 38,000
Stock Exchange NASDAQ
Ticker Symbol VTRS
Full Company Profile

Financial Performance

In 2023, Viatris's revenue was $15.43 billion, a decrease of -5.14% compared to the previous year's $16.26 billion. Earnings were $54.70 million, a decrease of -97.37%.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VTRS stock is "Sell." The 12-month stock price forecast is $11.0, which is a decrease of -7.87% from the latest price.

Price Target
$11.0
(-7.87% downside)
Analyst Consensus: Sell
Stock Forecasts

News

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

PITTSBURGH , March 27, 2024 /PRNewswire/ -- At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its ...

2 days ago - PRNewsWire

Idorsia and Viatris successfully close the transaction for the global research and development collaboration

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VT...

11 days ago - GlobeNewsWire

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

NEW YORK , March 11, 2024 /PRNewswire/ -- IN THE COURT OF COMMON PLEAS OF ALLEGHENY COUNTY, PENNSYLVANIA RAJESH PATEL, Individually and on Behalf of All Others Similarly Situated,                     ...

18 days ago - PRNewsWire

US FDA declines to approve Viatris's injection for multiple sclerosis

The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.

18 days ago - Reuters

Viatris forecasts strong 2024 sales on higher demand for branded drugs

Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma.

4 weeks ago - Reuters

Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

PITTSBURGH , Feb. 28, 2024 /PRNewswire/ -- Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1]   Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7...

4 weeks ago - PRNewsWire

Idorsia and Viatris enter into a significant global research and development collaboration

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.

4 weeks ago - GlobeNewsWire

Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collab...

4 weeks ago - PRNewsWire

Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results

PITTSBURGH , Feb. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financ...

7 weeks ago - PRNewsWire

10 Healthcare Stocks That Are Heating Up

The sector has seen one of the best starts to the year in decades, Goldman says.

2 months ago - Barrons

Charts turn bullish on health-care stocks as sector takes early lead in 2024

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...

2 months ago - Market Watch

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference i...

3 months ago - PRNewsWire

Drugmaker Viatris appoints Theodora Mistras as CFO

Global healthcare company Viatris on Friday appointed Theodora Mistras as its chief financial officer, effective March 1.

3 months ago - Reuters

Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH , De...

3 months ago - PRNewsWire

Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders

Board of Directors Elects Melina Higgins New Chair PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced that at its 2023 Annual Meeting of Sha...

3 months ago - PRNewsWire

Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe

BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars...

4 months ago - PRNewsWire

Why the Cheapest Stock in the S&P 500 Is No Bargain

Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed.

4 months ago - Barrons

Viatris to Participate in the Jefferies London Healthcare Conference

PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in Londo...

4 months ago - PRNewsWire

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: ...

Other symbols: TBPH
4 months ago - PRNewsWire

Viatris core profit beats on generic drugs strength

Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.

5 months ago - Reuters

Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]

Reports Total Revenues of $3.94 Billion; U.S. GAAP Net Earnings of $332 Million; Adjusted EBITDA of $1.36 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $834 Million; and Free Cash Fl...

5 months ago - PRNewsWire

Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance

PITTSBURGH , Oct. 30, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today it is hosting The Power of Partnership to Address Antimicrobial Resistance (AMR), a...

5 months ago - PRNewsWire

Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row

PITTSBURGH , Oct. 23, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023. Viatris has ...

5 months ago - PRNewsWire

Rajiv Malik to Retire as President of Viatris Effective April 1, 2024

PITTSBURGH , Oct. 20, 2023  /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company ...

5 months ago - PRNewsWire

Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking

PITTSBURGH , Oct. 18, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced it has been named to 3BL's annual 100 Best Corporate Citizens ranking, recognizing ...

5 months ago - PRNewsWire